Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12336982
Compositions and methods of modulating short-chain dehydrogenase activity
granted -
US 12336983
Inhibition of crystal growth of roflumilast
granted -
US 12337019
Vehicles for applying bacteria to skin, scalp, and hair
granted -
US 12336995
Combination therapies
granted -
US 12336974
Methods and compositions for preventing and treating auditory dysfunctions
granted -
US 12338231
N-heterocycle substituted tryptamine derivatives and methods of using
granted -
US 12338242
TYK2 inhibitors and uses thereof
granted -
US 12338199
Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
granted -
US 12338218
Crystal form of benzimidazole-2-one compound, solvate thereof, crystal form of solvate thereof, and preparation method thereof
granted -
US 12338249
Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea
granted -
US 12338274
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12338437
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 12338450
Gene therapy constructs for treating Wilson disease
granted -
US 12338438
Conjugated oligonucleotide compounds, methods of making and uses thereof
granted -
US 12338439
Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
granted -
WO 2025132620
PRÉPARATIONS DE CAPSULE MOLLE STABLES À REMPLISSAGE SOLIDE POUR PRINCIPES ACTIFS SENSIBLES À L'HUMIDITÉ
granted -
WO 2025133166
VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE
granted -
WO 2025133252
DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5
granted -
WO 2025133253
EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE
granted -
WO 2025137347
FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION
granted -
US 12344654
Mage A4 T cell receptors
granted -
US 12343357
Compositions and methods for modulating MECP2 expression
granted -
US 12344596
Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
granted -
US 12343321
Method for ameliorating or avoiding the adverse effects of exogenous gonadotropins on reproductive performance
granted -
US 12343388
Clostridioides difficile TcdB variants, vaccines and methods of use
granted -
US 12343397
Drug-resistant immune cells and methods of use thereof
granted -
US 12343394
CD38 modulating antibody agents
granted -
US 12343424
Photochemically stable, non-leaching, bridged polysilsesquioxane based sunscreens
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12343337
Compounds for increasing neural plasticity
granted -
US 12343342
Methods for treating soft tissue sarcoma
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12344665
Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12344842
Compositions and methods for treating and preventing macular degeneration
granted -
US 12343380
Expansion of TILs utilizing AKT pathways inhibitors
granted -
US 12343398
Biodegradable lipids for the delivery of active agents
granted -
US 12344585
Crystalline salts of a plasma kallikrein inhibitor
granted -
US 12344578
Salt forms of bempedoic acid and methods for using the same
granted -
US 12343432
Encapsulated probiotic
granted -
US 12343350
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted -
US 12344655
Gene-edited natural killer cells
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12345709
CLAUDIN18 antibodies and methods of treating cancer
granted -
US 12344677
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
granted -
US 12344656
Genetically engineered T cells having improved persistence in culture
granted -
US 12343448
Use of stem cells produced by stem cell generator in treatment of hematopoietic damage
granted -
US 12343381
Dosage regimen for pegylated interferon
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.